MPM Capital
VC Fund
Cambridge, United States
MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.
- Total investments:
- 239
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $850M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries MPM Capital invests in
Stages MPM Capital invests in
Countries MPM Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 18 contacts → | |||
Round size
- Series A
- $10M–$80M
- Series B
- $20M–$116M
- Series C
- $12M–$109M
Investment Focus
Industry
- Biotechnology 114 (48%)
- Health Care 73 (31%)
- Therapeutics 47 (20%)
- Pharmaceutical 46 (19%)
- Medical 36 (15%)
Stage
- Series B 52 (22%)
- Series A 51 (21%)
- Series C 39 (16%)
- Series D 17 (7%)
- Funding Round 13 (5%)
Country
- United States 119 (50%)
- Canada 3 (1%)
- United Kingdom 3 (1%)
- Germany 2 (1%)
- Italy 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dan Hicklin
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
David P. Ryan
Medical and Scientific Advisor
|
Medical and Scientific Advisor | Total investments: 1 | Find email | |
Detlev Biniszkiewicz
Executive Partner
|
Executive Partner | Total investments: 3 | Find email | |
Patrick Baeuerle
Excutive Partner
|
Excutive Partner | Total investments: 2 | Find email | |
Uciane Scarlett
Principal
|
Principal | Total investments: 4 | Find email | |
| See all 18 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| K2 Therapeutics creates advanced antibody-based therapies focused on difficult multi-pass membrane targets to address unmet disease needs. | $50M / Seed / Aug 11, 2026 | ||
| Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M / Series B / Dec 01, 2025 | ||
| Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications. | $133M / Series A / Sep 16, 2025 | ||
| Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer. | $100M / Series C / Jan 14, 2025 | ||
| āshibio creates treatments for rare bone and connective tissue ailments, potentially preventing symptoms or slowing their course. | $40M / Series A / Jun 20, 2024 | ||
| Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery anddevelopment, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases. | $80M / Series C / Feb 22, 2024 | ||
| Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders. | $94M / Series A / Feb 15, 2024 | ||
| NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. | $42.5M / Series B / Feb 14, 2024 | ||
AstronauTx
|
AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes. | $58.7M / Series A / Oct 08, 2023 | |
| Early stage biotechnology start-up developing next generation cytokine therapeutics | $20M / Series B / Sep 28, 2023 | ||
| See all 239 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does MPM Capital invest in?
MPM Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 239 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is MPM Capital's check size?
MPM Capital typically joins rounds of $10M–$80M at Series A, $20M–$116M at Series B and $12M–$109M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds MPM Capital participates in.
How do I contact MPM Capital?
Public channels for MPM Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at MPM Capital?
The team at MPM Capital includes Dan Hicklin (Managing Director), David P. Ryan (Medical and Scientific Advisor) and Detlev Biniszkiewicz (Executive Partner), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
